[1]黄定国,岑令平,张安琳,等.频域光学相干断层扫描观察康柏西普治疗老年性黄斑变性患者黄斑结构的变化[J].眼科新进展,2018,38(12):1157-1160.[doi:10.13389/j.cnki.rao.2018.0273]
　HUANG Ding-Guo,CEN Ling-Ping,ZHANG An-Lin,et al.Changes in macular structure after treatment with conbercept for age-related macular degeneration by spectral domain optical coherence tomography[J].Recent Advances in Ophthalmology,2018,38(12):1157-1160.[doi:10.13389/j.cnki.rao.2018.0273]
点击复制

频域光学相干断层扫描观察康柏西普治疗老年性黄斑变性患者黄斑结构的变化/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年12期
页码:
1157-1160
栏目:
应用研究
出版日期:
2018-12-05

文章信息/Info

Title:
Changes in macular structure after treatment with conbercept for age-related macular degeneration by spectral domain optical coherence tomography
作者:
黄定国; 岑令平; 张安琳; 陈伟奇
515041　广东省汕头市，汕头大学·香港中文大学联合汕头国际眼科中心
Author(s):
HUANG Ding-Guo; CEN Ling-Ping; ZHANG An-Lin; CHEN Wei-Qi
Department of the Joint Shantou International Eye Center of Shantou University and the Chinese University of Hongkong，Shantou 515041，Guangdong Province，China
关键词:
光学相干断层扫描; 老年性黄斑变性; 康柏西普
Keywords:
optical coherence tomography; age-related macular degeneration; conbercept
分类号:
R774
DOI:
10.13389/j.cnki.rao.2018.0273
文献标志码:
A
摘要:
目的　利用频域光学相干断层扫描（optical coherence tomography，OCT）观察湿性老年性黄斑变性（age-related macular degeneration，AMD）患者经康柏西普治疗后黄斑中心凹结构的变化并分析与最佳矫正视力（best corrected visual acuity,BCVA）的相关性。方法　经荧光素眼底血管造影确诊为湿性AMD的患者纳入研究，所有患者接受连续3个月、每个月玻璃体内注射一次康柏西普的常规疗法，记录治疗前及各次注射后1个月的BCVA以及频域OCT的特征（黄斑中心凹视网膜厚度、视网膜内积液、视网膜下积液、视网膜色素上皮层脱离、视网膜下纤维化等）。结果　经过3次注射治疗后，BCVA从治疗前的（0.98±0.55）LogMAR提高到治疗后的（0.69±0.43）LogMAR（P<0.01），黄斑中心凹视网膜厚度从治疗前的（449.07±245.19）μm降低到治疗后的（232.76±103.93）μm（P<0.01），其中初次注射后第1个月BCVA和黄斑中心凹视网膜厚度的改善最为明显；3次注射后视网膜内积液或视网膜下积液消退组BCVA改善并没有明显优于各自的未消退组（均为P>0.05），但单纯视网膜下积液组BCVA明显优于单纯视网膜内积液组和混合积液组（F=6.168，P=0.007）。结论　频域OCT是一种评价黄斑结构改变的有效手段，为临床分析注射康柏西普术后视力的变化提供了有力的依据。
Abstract:
Objective　To study the association between visual outcome and changes in foveal structure after treatment with conbercept for wet age-related macular degeneration （AMD） with spectral domain optical coherence tomography （OCT）.Methods　Patients with wet AMD diagnosed by fluorescein fundus angiography were included.All the patients received intravitreal injection of conbercept monthly for 3 months.Best corrected visual acuity （BCVA） and OCT findings ［foveal retinal thickness，intraretinal fluid （IRF），subretinal fluid （SRF），pigment epithelium detachment and subretinal fibrosis］ at baseline and one month after each injection were evaluated.Results　Mean BCVA improved from （0.98±0.55） LogMAR at baseline to （0.69±0.43） LogMAR at the 3rd month （P<0.01）.The mean foveal thickness reduced from （449.07±245.19）μm at baseline to （232.76±103.93）μm at the 3rd month （P<0.01）.The most significant improvement occurred in the first month after treatment.After three injections，patients with or without persisting IRF/ SRF benefitted without statistically significant differences （P>0.05）.The mean BCVA of subretinal fluid group was significantly better than that of intraretinal fluid group and mixed group （F=6.168，P=0.007）.Conclusion　Spectral domain OCT is an effective device for evaluating changes in macular structure.It provides strong evidence for clinical analysis of postoperative visual acuity changes in wet AMD patients receiving intravitreal conbercept treatment.

参考文献/References:

［1］　NGUYEN T T，GUYMER R.Conbercept （KH-902） for the treatment of neovascular age-related macular degeneration［J］.Expert Rev Clin Pharmacol，2015，8（5）：541-548.
［2］　LI X，XU G，WANG Y，XU X，LIU X，TANG S，et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration：results from a 12-month randomized phase 2 study：AURORA study［J］.Ophthalmology，2014，121（9）：1740-1747.
［3］　BROWN D M，KAISER P K，MICHELS M，SOUBRANE G，HEIER J S，KIM R Y，et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration［J］.N Engl J Med，2006，355（14）：1432-1444.
［4］　SEGAL O，BARAYEV E，NEMET A Y，MIMOUNI M.Predicting response of exudative age-related macular degeneration to bevacizumab based on spectralis optical coherence tomography［J］.Retina，2016，36（2）：259-263.
［5］　JOERES S，TSONG J W，UPDIKE P G，COLLINS A T，DUSTIN L，WALSH A C，et al.Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration［J］.Invest Ophthalmol Vis Sci，2007，48（9）：4300-4307.
［6］　SINGH R P，FU E X，SMITH S D，WILLIAMS D R，KAISER P K.Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration：an optical coherence tomography study［J］.Br J Ophthalmol，2009，93（10）：1353-1358.
［7］　MICHALEWSKI J，NAWROCKI J，IZDEBSKI B，MICHALEWSKA Z.Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration，12-months results［J］.Indian J Ophthalmol，2014，62（5）：554-560.
［8］　EBNETER A，GEKKIEV B，CHANANA B，WOLF S，ZINKERNAGEL M S.The presence of intra- or subretinal fluid during the loading phase in the treatment of exudative age-related macular degeneration with intravitreal ranibizumab assessed by optical coherence tomography［J］.Ophthalmologica，2015，234（2）：61-66.
［9］　PARK D H，SUN H J，LEE S J.A comparison of responses to intravitreal bevacizumab，ranibizumab，or aflibercept injections for neovascular age-related macular degeneration［J］.Int Ophthalmol，2016，37（5）：1-10.
［10］　LI X，LUO H，ZUO C，ZHANG Z，ZHANG J，ZHANG M.Conbercept in patients with treatment-naive neovascular age-related macular degeneration in real-life setting in China［J］.Retina，2018，［Epub ahead of print］.
［11］　PENHA F M，GREGORI G，GARCIA FILHO C A，YEHOSHUA Z，FEUER W J，ROSENFELD P J.Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy［J］.Retina，2013，33（3）：459-466.
［12］　WALDSTEIN S M，SIMADER C，STAURENGHI G，CHONG N V，MITCHELL P，JAFFE G J，et al.Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the view trials［J］.Ophthalmology，2016，123（7）：1521-1529.
［13］　JAFFE G J，MARTIN D F，TOTH C A，DANIEL E，MAGUIRE M G，YING G S，et al.Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology，2013，120（9）：1860-1870.
［14］　DANIEL E，TOTH C A，GRUNWALD J E，JAFFE G J，MARTIN D F，FINE S L，et al.Risk of scar in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology，2014，121（3）：656-666.
［15］　BARIKIAN A，MAHFOUD Z，ABDULAAL M，SAFAR A，BAS-HSHUR Z F.Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration［J］.Am J Ophthalmol，2015，159（1）：131-137.
［16］　HWANG J C，DEL PRIORE L V，FREUND K B，CHANG S，IRANMANESH R.Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration［J］.Ophthalmic Surg Lasers Imaging，2011，42（1）：6-11.
［17］　BLOCH S B，LUND-ANDERSEN H，SANDER B，LARSEN M.Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab［J］.Am J Ophthalmol，2013，156（1）：116-124.

相似文献/References:

[1]陈晓 李舒茵 牛超 李建新 陈慷.先天性视网膜劈裂症的影像学观察[J].眼科新进展,2012,32(11):000.
[2]闵红波 刘小红 花雷 韩文龙 储明慧 邵娟英.近视对OCT测量视网膜神经纤维层厚度的影响[J].眼科新进展,2012,32(12):000.
[3]张译心 巩琰 戴艳丽 黄厚斌 魏世辉.特发性脱髓鞘性视神经炎视网膜神经纤维层厚度和黄斑厚度的变化特点[J].眼科新进展,2013,33(2):000.
[4]马兰茗 金喜浓 金丽.光学相干断层扫描测量下方泪河高度诊断2型糖尿病患者眼干燥症的可行性[J].眼科新进展,2013,33(2):000.
[5]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[6]陈月芹 黄振平 薛春燕 葛轶睿.有晶状体眼虹膜固定型人工晶状体植入术后房角宽度的改变[J].眼科新进展,2013,33(6):000.
[7]杨世琳 杜改萍 郝玉华.频域OCT观察Vogt-小柳-原田病患者病程中黄斑中心凹的图像特点[J].眼科新进展,2013,33(6):000.
[8]辛晨 汪军 刘广峰 孟忻.增强成像技术光学相干断层扫描在在体脉络膜结构研究中的应用[J].眼科新进展,2013,33(6):000.
[9]马英慧 张铁民 齐建平.原发性开角型青光眼与慢性原发性闭角型青光眼视网膜神经纤维层厚度与视野缺损的关系[J].眼科新进展,2013,33(7):000.
[10]张海涛 杨玉新 毛永 丁晓丽 秦海霞 梁长华 郭英昌.青光眼与非炎症性缺血型视神经病变的傅立叶OCT扫描视神经形态学对比[J].眼科新进展,2013,33(8):000.
[11]吴若欣,徐洁慧,温积全,等.玻璃体内注射康柏西普对渗出性老年性黄斑变性患者脉络膜厚度的影响[J].眼科新进展,2016,36(12):1172.[doi:10.13389/j.cnki.rao.2016.0312]
　WU Ruo-Xin,XU Jie-Hui,WEN Ji-Quan,et al.Effects of intravitreal conbercept injections on choroidal thickness in exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2016,36(12):1172.[doi:10.13389/j.cnki.rao.2016.0312]

备注/Memo

备注/Memo:
广东省医学科学技术研究基金项目（编号：A2016550）
更新日期/Last Update: 2018-12-04